SETTING: Süreyyapaşa Centre for Chest Diseases and Thoracic Surgery, Istanbul, Turkey. OBJECTIVE: To report the frequency of treatment side effects in cases of multidrug-resistant (MDR-TB) tuberculosis. DESIGN: A retrospective review of the medical records of 263 patients who received individualised treatment for MDR-TB between April 1992 and June 2004. RESULTS: One or more side effects developed in 182 cases (69.2%). These effects led the clinicians to withdraw one or more drugs from the treatment regimen in 146 cases (55.5%). Side effects observed most frequently included: ototoxicity (41.8%), psychiatric disorders (21.3%), gastrointestinal disturbance (14.0%), arthralgia (11.4%), epileptic seizures (9.9%), hepatitis (4.5%), and dermatological effects (4.5%). At the time of analysis, treatment was successful in 204 (77.6%) cases. Fifty-nine patients (22.4%) had poor outcomes. CONCLUSION: Timely and aggressive management of drug side effects means that high side effect rates in MDR-TB treatment need not compromise success rates.
SETTING: Süreyyapaşa Centre for Chest Diseases and Thoracic Surgery, Istanbul, Turkey. OBJECTIVE: To report the frequency of treatment side effects in cases of multidrug-resistant (MDR-TB) tuberculosis. DESIGN: A retrospective review of the medical records of 263 patients who received individualised treatment for MDR-TB between April 1992 and June 2004. RESULTS: One or more side effects developed in 182 cases (69.2%). These effects led the clinicians to withdraw one or more drugs from the treatment regimen in 146 cases (55.5%). Side effects observed most frequently included: ototoxicity (41.8%), psychiatric disorders (21.3%), gastrointestinal disturbance (14.0%), arthralgia (11.4%), epilepticseizures (9.9%), hepatitis (4.5%), and dermatological effects (4.5%). At the time of analysis, treatment was successful in 204 (77.6%) cases. Fifty-nine patients (22.4%) had poor outcomes. CONCLUSION: Timely and aggressive management of drug side effects means that high side effect rates in MDR-TB treatment need not compromise success rates.
Authors: Grania Brigden; Bern-Thomas Nyang'wa; Philipp du Cros; Francis Varaine; Jennifer Hughes; Michael Rich; C Robert Horsburgh; Carole D Mitnick; Eric Nuermberger; Helen McIlleron; Patrick P J Phillips; Manica Balasegaram Journal: Bull World Health Organ Date: 2013-10-25 Impact factor: 9.408
Authors: H Hong; D W Dowdy; K E Dooley; H W Francis; C Budhathoki; H-R Han; J E Farley Journal: Int J Tuberc Lung Dis Date: 2020-01-01 Impact factor: 2.373
Authors: Sarah K Brode; Robert Varadi; Jane McNamee; Nina Malek; Sharon Stewart; Frances B Jamieson; Monica Avendano Journal: Can Respir J Date: 2014-12-10 Impact factor: 2.409
Authors: James C M Brust; N Sarita Shah; Theo L van der Merwe; Sheila Bamber; Yuming Ning; Moonseong Heo; Anthony P Moll; Marian Loveday; Umesh G Lalloo; Gerald H Friedland; Neel R Gandhi Journal: J Acquir Immune Defic Syndr Date: 2013-04-01 Impact factor: 3.731
Authors: Jae Chol Choi; Song Yong Lim; Gee Young Suh; Man Pyo Chung; Hojoong Kim; O Jung Kwon; Nam Yong Lee; Young Kil Park; Gil Han Bai; Won Jung Koh Journal: J Korean Med Sci Date: 2007-08 Impact factor: 2.153